Drug
Rina S
Rina S: highest development phase Phase 3, developed by Genmab. 7 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Genmab
Trials
| Drug | Phase | Indication |
|---|---|---|
| Rina-S NCT07564141 | Phase 3 | Platinum-Sensitive Ovarian Cancer |
| Rina-S NCT07166094 | Phase 3 | Endometrial Cancer |
| Rina-S NCT06619236 | Phase 3 | Platinum-resistant Ovarian Cancer |
| Rina-S NCT07604766 | Phase 3 | Platinum-resistant Ovarian Cancer |
| Rina-S NCT07859215 | Phase 3 | Ovarian Cancer |
| Rina-S NCT07539311 | Phase 2 | Gastrointestinal Cancers |
| Rina-S NCT05579366 | Phase 1/2 | High Grade Epithelial Ovarian Cancer |
Latest
No recent events.
Follow Rina S on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.